^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | urabrelimab (SRF231) (CD47 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 2196: SRF231, a fully human CD47 antibody, potentiates the effects of opsonizing antibodies and cytotoxic chemotherapies in preclinical cancer models
Published date:
05/15/2020
Excerpt:
In vivo, SRF231 monotherapy induced anti-tumor activity and significantly increased median survival time in preclinical EGFR mutant (H1975) and EGFR wildtype (A549) NSCLC xenograft models.
DOI:
10.1158/1538-7445.AM2020-2196
